Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Biomarker ResearchOpen Access

Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDávid KegyesABAnamaria BancosAȚAdrian Bogdan Țigu

Discussion

Loading...

Member takes

Overview

This analysis explores CELMoDs' role in enhancing immunotherapy responses in multiple myeloma, suggesting significant treatment advancements.

Key Points

  • Combining CELMoDs improves response rates in multiple myeloma patients, and it targets both IKZF1 and IKZF3.
  • CELMoDs are reported to bind 10–20 times more effectively than traditional agents, enhancing therapy efficacy.
  • The study reviews emerging evidence from key hematology conventions to support combining novel therapies in treatment.
  • Despite improved survival rates, multiple myeloma remains incurable, highlighting the need for innovative treatment strategies.

Cite This Study

Kegyes et al. (2025) studied this question.

synapsesocial.com/papers/68c1c9d254b1d3bfb60f2a4chttps://doi.org/10.1186/s40364-025-00825-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of a Primary Target of Thalidomide Teratogenicity2010 · 2,136 citations
  2. 2EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies2018 · 59 citations
  3. 3CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma2019 · 20 citations
  4. 4Molecular glue CELMoD compounds are regulators of cereblon conformation2022 · 210 citations
  5. 5Targeted immunotherapy: harnessing the immune system to battle multiple myeloma2024 · 30 citations